Unbound GHK for liver regeneration — RU2214269C1
M. Yu. Smakhtin, I. A. Shveinov, A. A. Konoplya, L. A. Sever’yanova, I. I. Bobyntsev · 2003 · RU2214269C1 · patent family 31988876
Published 2003-10-20.
Reported patent results
Narrative findings; numerical extraction incomplete
Mitotic activity increased from 1.5 µg/kg without further increases at higher doses. Higher doses produced more dystrophic changes. Patent claim and description disagree on dose units.
Wistar rats, 8–10 per group; saline controls and toxic-liver-injury comparison. Five daily intraperitoneal GHK injections; histology assessed the day after the last injection.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| GHK dose series and mitotic activity | Five daily intraperitoneal injections: 0.5 µg/kg had no substantial activity; 1.5 µg/kg increased mitotic index; 50, 150 and 450 µg/kg did not further increase it | Healthy Wistar rats, 8–10 per group; numerical figure values and uncertainty not extracted · Histology the day after the fifth injection |
| Higher-dose tissue changes | Dystrophic changes described at 50, 150 and 450 µg/kg, especially at 450 µg/kg | No dystrophic changes described at 1.5 µg/kg in the healthy-animal example; not proof of long-term safety |
| Toxic-liver-injury example | Both 1.5 and 150 µg/kg increased mitotic index; dystrophic changes were greater with 150 µg/kg | 8–10 rats per group; GHK concurrent with toxic injury. Patent used intramuscular tetrachloromethane exposure; do not merge with the thesis acute intragastric model. |
| Claim versus description dose units | Description: 1.5 µg/kg; claim: 1.5 µg/g | 1,000-fold discrepancy retained; no corrected legal claim or safe human dose asserted |
| Numerical extraction and clinical gap | No numerical mitotic-index graph values extracted; no human clinical outcomes | Patent text checked; linked PDF not retrieved. Proposed clinical use is not a measured result |
The measured endpoint was animal hepatocyte proliferation, alongside adverse histology at higher exposures. Copper binding was not part of the tested preparation. The patent and 2002–2004 journal/thesis reports are potentially overlapping disclosures, not independent efficacy replications. Dose units conflict between claim and description.
Source for the extracted data ↗ · Checked 2026-11-08
Patent claims and provenance
Use. Experimental use of unbound Gly-His-Lys to stimulate physiological and reparative hepatocyte proliferation. Description: five daily intraperitoneal injections in rats.
Animal patent disclosure, not a human trial or GHK-Cu administration study. Description uses µg/kg while the claim prints µg/g; this 1,000-fold discrepancy is unresolved. Related journal and thesis reports may share experiments.
- Publication
- RU2214269C1 ↗ · 2003-10-20
- Earliest priority / filing
- 2002-03-07 / 2002-03-07
- Original applicant / assignee
- Kursk State Medical University
- Indexed status
- Index reports lapse for nonpayment; official status not independently verified · checked 2026-11-08
- Patent family
- 31988876 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Способ стимуляции физиологической и репаративной регенерации печени
Inventors: M. Yu. Smakhtin; I. A. Shveinov; A. A. Konoplya; L. A. Sever’yanova; I. I. Bobyntsev.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Animal patent disclosure, not a human trial or GHK-Cu administration study. Description uses µg/kg while the claim prints µg/g; this 1,000-fold discrepancy is unresolved. Related journal and thesis reports may share experiments.
- The measured endpoint was animal hepatocyte proliferation, alongside adverse histology at higher exposures. Copper binding was not part of the tested preparation. The patent and 2002–2004 journal/thesis reports are potentially overlapping disclosures, not independent efficacy replications. Dose units conflict between claim and description.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-31988876. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-08. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: M. Yu. Smakhtin, I. A. Shveinov, A. A. Konoplya, L. A. Sever’yanova, I. I. Bobyntsev. Unbound GHK for liver regeneration — RU2214269C1 RU2214269C1 · patent family 31988876 2003.
Molekul research summary: https://molekul.io/research/patent-ru2214269c1. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry